Doubts, page-5

"The algorithm is not allowed to learn in the upcoming trials."
That's not correct. What they have said is that they cannot change it during the trial.

The huge data set from this trial becomes just as valuable as the algorithm itself because you cannot get FDA approval without both the product and the proof.

To quote one article I have read "Long story short: Self learning algorithms work on the data which is provided to them." Therefore the more data you give them the more they learn and the more accurate they will become.

Nonetheless I agree there is a delay of 3-6 months from the timetable discussed just 6 months ago. But in the end I do not think that it will matter too much because they could have FDA approval but no staff to help commercialise it. Now we have a situation where the commercialisation activities (e.g. hiring of staff) is going to happen concurrently and Resapp will be able to release the product to market shortly after FDA approval.